Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.

× No keyword cloud information.

18 in total

Review 1. Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance.

Authors: Judi Anne B Ramiscal; Aminah Jatoi
Journal: Curr Oncol Rep Date: 2012-08 Impact factor: 5.075

2. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

Authors: Nancy E Kemeny; William R Jarnagin; Marinela Capanu; Yuman Fong; Alexandra N Gewirtz; Ronald P Dematteo; Michael I D'Angelica
Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544

3. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results?

Authors: Nancy E Kemeny; Lawrence Schwartz; Mithat Gönen; Adam Yopp; David Gultekin; Michael I D'Angelica; Yuman Fong; Dana Haviland; Alexandra N Gewirtz; Peter Allen; William R Jarnagin
Journal: Oncology Date: 2011-06-14 Impact factor: 2.935

4. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.

Authors: Sophie Dupuis-Girod; Alexis Ambrun; Evelyne Decullier; Géraldine Samson; Adeline Roux; Anne-Emmanuelle Fargeton; Catherine Rioufol; Verane Schwiertz; François Disant; François Chapuis; Yves Donazzolo; Gilles Paintaud; Patrick Edery; Frederic Faure
Journal: MAbs Date: 2014-01-30 Impact factor: 5.857

5. Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.

Authors: Judi Anne B Ramiscal; Aminah Jatoi
Journal: Acta Oncol Date: 2010-11-26 Impact factor: 4.089

Review 6. Effect of tyrosine kinase inhibitors on wound healing and tissue repair: implications for surgery in cancer patients.

Authors: Devron R Shah; Shamik Dholakia; Rashmi R Shah
Journal: Drug Saf Date: 2014-03 Impact factor: 5.606

Review 10. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

Authors: Kelly L Snider; Michael L Maitland
Journal: Target Oncol Date: 2009-04-17 Impact factor: 4.493

Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.